Was this an interim analysis or final readout, and which population and comparator were studied?
YOUR PRIVATE STARTING POINT
Compare with what you saved.
Save a milestone to your account’s Notebook. Reopen its original snapshot here and compare with this reviewed catalog. Email subscriptions use a separate opt-in.
Gilead published results from a PURPOSE 1 interim analysis and reported a committee recommendation to stop the blinded phase. This interim announcement was earlier than the previously indicated update window; it was not final regulatory approval.
These selected company announcements preserve publication dates separately from ORION’s later recording times. Registry completion dates and follow-up research questions are separate from company announcements; this historical release does not establish current guidance or continuous monitoring.